Galectin Therapeutics Stock (NASDAQ:GALT)


RevenueOwnershipFinancialsChart

Previous Close

$1.04

52W Range

$0.73 - $4.27

50D Avg

$2.51

200D Avg

$2.64

Market Cap

$55.46M

Avg Vol (3M)

$438.89K

Beta

0.63

Div Yield

-

GALT Company Profile


Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Sep 04, 2002

Website

GALT Performance


GALT Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-41.07M$-38.35M$-30.18M
Net Income$-41.07M$-39.20M$-30.98M
EBITDA$-41.07M$-38.30M$-30.18M
Basic EPS$-0.68$-0.66$-0.53
Diluted EPS$-0.68$-0.66$-0.53

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 16Mar 28, 17 | 12:33 PM
Q4 15Mar 15, 16 | 2:20 PM

Peer Comparison


TickerCompany
PTCTPTC Therapeutics, Inc.
IKTInhibikase Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
VKTXViking Therapeutics, Inc.
AKROAkero Therapeutics, Inc.
SRPTSarepta Therapeutics, Inc.
ONCYOncolytics Biotech Inc.
DMACDiaMedica Therapeutics Inc.
ETNB89bio, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
ACLXArcellx, Inc.
HEPAHepion Pharmaceuticals, Inc.
MISTMilestone Pharmaceuticals Inc.